Quick Answer
REGENXBIO Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $170.44 million for the year ending 2025.
- REGENXBIO Inc. showed an increase of +104.5% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from REGENXBIO Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $455.0 thousand | Q2 2017: $6.56 million | Q3 2017: $1.34 million | Q4 2017: $2.04 million | Q1 2018: $132.39 million | Q2 2018: $40.03 million | Q3 2018: $5.31 million | Q4 2018: $40.78 million | Q1 2019: $884.0 thousand | Q2 2019: $7.88 million | Q3 2019: $14.70 million | Q4 2019: $11.77 million | Q1 2020: $17.64 million | Q2 2020: $16.57 million | Q3 2020: $98.91 million | Q4 2020: $21.45 million | Q1 2021: $18.88 million | Q2 2021: $22.04 million | Q3 2021: $30.77 million | Q1 2022: $22.22 million | Q2 2022: $32.65 million | Q3 2022: $26.51 million | Q1 2023: $19.14 million | Q2 2023: $19.98 million | Q3 2023: $28.91 million | Q1 2024: $15.62 million | Q2 2024: $22.30 million | Q3 2024: $24.20 million | Q1 2025: $89.01 million | Q2 2025: $21.36 million | Q3 2025: $29.73 million.
- Over the full 10 years of available data (2016 to 2025), REGENXBIO Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 3,614.1%.
- Historical annual values: Fiscal year 2025: $170.44 million | Fiscal year 2024: $83.33 million | Fiscal year 2023: $90.24 million | Fiscal year 2022: $112.72 million | Fiscal year 2021: $470.35 million | Fiscal year 2020: $154.57 million | Fiscal year 2019: $35.23 million | Fiscal year 2018: $218.51 million | Fiscal year 2017: $10.39 million | Fiscal year 2016: $4.59 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: